HUP0302201A2 - Oldható CTLA4 mutáns molekulák és alkalmazásuk - Google Patents

Oldható CTLA4 mutáns molekulák és alkalmazásuk

Info

Publication number
HUP0302201A2
HUP0302201A2 HU0302201A HUP0302201A HUP0302201A2 HU P0302201 A2 HUP0302201 A2 HU P0302201A2 HU 0302201 A HU0302201 A HU 0302201A HU P0302201 A HUP0302201 A HU P0302201A HU P0302201 A2 HUP0302201 A2 HU P0302201A2
Authority
HU
Hungary
Prior art keywords
ctla4
soluble
soluble ctla4
ctla4 mutant
fusion protein
Prior art date
Application number
HU0302201A
Other languages
English (en)
Inventor
Jurgen Bajorath
Peter S. Linsley
Joseph R. Naemura
Robert J. Peach
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0302201A2 publication Critical patent/HUP0302201A2/hu
Publication of HUP0302201A3 publication Critical patent/HUP0302201A3/hu
Publication of HU228137B1 publication Critical patent/HU228137B1/hu
Priority to HUS1300012C priority Critical patent/HUS1300012I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan oldható CTLA4 mutáns molekulákra vonatkozik, amelyekfelismerik és erősebb aviditással kötik a CD80-at és CD86-ot, mint avad típusú CTLA4. A találmány szerinti oldható CTLA4 mutáns molekulaegy fúziós protein, amely egy szignálpeptidet, a CTLA4 extracellulárisdoménjét és a humán immunglobulin egy konstans régióját tartalmazza. Amutagenezist helyre irányuló mutagenezissel, PCR alkalmazásávalvégzik. A mutagenizált fúziós proteint pedig géntechnológiaieljárásokkal állítják elő. A találmány szerinti oldható CTLA4Ig mutánsmolekula olyan immunrendszeri betegségek kezelésére alkalmazható, aholimmunszuppresszióra van szükség. Ilyenek pédául az autoimmunbetegségek, immunproliferatív betegségek, szövetátültetés utánikilökődés (graft versus host) stb. Ó
HU0302201A 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof HU228137B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (3)

Publication Number Publication Date
HUP0302201A2 true HUP0302201A2 (hu) 2003-10-28
HUP0302201A3 HUP0302201A3 (en) 2010-01-28
HU228137B1 HU228137B1 (en) 2012-12-28

Family

ID=26908652

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0302201A HU228137B1 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Country Status (41)

Country Link
EP (3) EP1248802B9 (hu)
JP (1) JP4328525B2 (hu)
KR (2) KR100889887B1 (hu)
CN (2) CN1309735C (hu)
AR (1) AR031699A1 (hu)
AT (1) ATE271066T1 (hu)
AU (2) AU2001263466C1 (hu)
BE (1) BE2011C041I2 (hu)
BR (1) BRPI0111191B8 (hu)
CA (1) CA2409748C (hu)
CY (2) CY2011019I1 (hu)
CZ (1) CZ304451B6 (hu)
DE (2) DE60104282T2 (hu)
DK (1) DK1248802T3 (hu)
EC (1) ECSP024365A (hu)
EE (2) EE05458B1 (hu)
EG (1) EG24459A (hu)
ES (2) ES2571852T3 (hu)
FR (1) FR11C0053I2 (hu)
GE (1) GEP20053658B (hu)
HK (2) HK1048126B (hu)
HU (2) HU228137B1 (hu)
IL (1) IL152315A (hu)
LT (1) LT5133B (hu)
LU (1) LU91902I2 (hu)
LV (1) LV12994B (hu)
MX (1) MXPA02011534A (hu)
MY (1) MY136113A (hu)
NO (2) NO330797B1 (hu)
PE (1) PE20011338A1 (hu)
PL (1) PL206267B1 (hu)
PT (1) PT1248802E (hu)
RU (1) RU2283847C2 (hu)
SI (1) SI1248802T1 (hu)
SK (1) SK288131B6 (hu)
TR (1) TR200402703T4 (hu)
TW (2) TWI314933B (hu)
UA (1) UA87432C2 (hu)
UY (1) UY26723A1 (hu)
WO (1) WO2001092337A2 (hu)
ZA (1) ZA200208944B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2001273174B2 (en) * 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DE60225914T2 (de) 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
WO2004058800A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US10508144B2 (en) * 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2716657A3 (en) 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
KR20170091801A (ko) * 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
SG192905A1 (en) 2011-02-23 2013-09-30 Amgen Inc Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
PL3207938T3 (pl) * 2012-05-11 2020-07-13 Medimmune Limited Warianty CTLA-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
KR20150033703A (ko) * 2012-06-27 2015-04-01 오르반 바이오테크 엘엘씨 당뇨병 치료를 위한 ctla4 융합 단백질
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
MX2016009084A (es) 2014-01-13 2016-10-13 Amgen Inc Regulacion del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteinas recombinantes.
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
PL3152317T3 (pl) 2014-06-04 2019-08-30 Amgen Inc. Sposoby zbierania hodowli ssaczych komórek
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
EP3515489A4 (en) * 2016-09-19 2020-05-06 Oncoimmune, Inc. CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
CA3172625A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
IL299060A (en) 2020-06-18 2023-02-01 Regeneron Pharma A heavy peptide approach for accurate measurement of lysine with an unprocessed carboxyl terminus
CN116601279A (zh) 2020-07-28 2023-08-15 思进股份有限公司 用于生产多肽的方法和系统
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
US20240010737A1 (en) 2022-03-02 2024-01-11 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
JP3722375B2 (ja) * 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
AU2001273174B2 (en) * 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule

Also Published As

Publication number Publication date
HUS1300012I1 (hu) 2016-08-29
PL206267B1 (pl) 2010-07-30
HUP0302201A3 (en) 2010-01-28
UY26723A1 (es) 2001-12-28
MY136113A (en) 2008-08-29
CZ20023892A3 (cs) 2003-09-17
UA87432C2 (uk) 2009-07-27
ECSP024365A (es) 2003-03-31
EP1536234A3 (en) 2009-06-03
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
EE05557B1 (et) 2012-08-15
BRPI0111191B8 (pt) 2021-05-25
BE2011C041I2 (hu) 2020-08-20
EP1248802B9 (en) 2005-05-11
NO20025656L (no) 2002-11-25
HK1071931A1 (zh) 2005-08-05
FR11C0053I2 (fr) 2013-01-11
LV12994B (en) 2003-08-20
CY1117625T1 (el) 2017-04-26
EE05458B1 (et) 2011-08-15
PL366231A1 (en) 2005-01-24
CA2409748C (en) 2008-09-16
ES2225549T3 (es) 2005-03-16
TWI319405B (en) 2010-01-11
EG24459A (en) 2009-07-16
EP1536234B1 (en) 2016-03-16
NO330797B1 (no) 2011-07-18
MXPA02011534A (es) 2004-08-12
WO2001092337A2 (en) 2001-12-06
JP2004511213A (ja) 2004-04-15
NO2011027I1 (no) 2012-01-09
TW200906857A (en) 2009-02-16
KR100895134B1 (ko) 2009-05-04
DE122011100063I1 (de) 2012-06-14
ZA200208944B (en) 2004-02-13
HK1048126A1 (en) 2003-03-21
AU6346601A (en) 2001-12-11
EP1248802B1 (en) 2004-07-14
NO20025656D0 (no) 2002-11-25
PT1248802E (pt) 2004-11-30
PE20011338A1 (es) 2002-01-13
JP4328525B2 (ja) 2009-09-09
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
BR0111191A (pt) 2004-07-06
AU2001263466C1 (en) 2006-10-26
CZ304451B6 (cs) 2014-05-14
EE201100050A (et) 2011-10-17
ES2571852T3 (es) 2016-05-27
SI1248802T1 (en) 2005-02-28
IL152315A (en) 2010-04-15
KR20030009502A (ko) 2003-01-29
RU2283847C2 (ru) 2006-09-20
CN101255192A (zh) 2008-09-03
CN1441810A (zh) 2003-09-10
ATE271066T1 (de) 2004-07-15
AR031699A1 (es) 2003-10-01
TWI314933B (en) 2009-09-21
AU2001263466B2 (en) 2006-04-27
IL152315A0 (en) 2003-05-29
DK1248802T3 (da) 2004-11-15
KR100889887B1 (ko) 2009-03-24
TR200402703T4 (tr) 2004-11-22
LT2002114A (en) 2003-12-29
CN1309735C (zh) 2007-04-11
EE200200659A (et) 2004-06-15
DE60104282D1 (de) 2004-08-19
EP3029062A1 (en) 2016-06-08
GEP20053658B (en) 2005-11-10
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
SK15702002A3 (sk) 2004-01-08
CA2409748A1 (en) 2001-12-06
HK1048126B (zh) 2005-03-04
CY2011019I1 (el) 2016-12-14
BRPI0111191B1 (pt) 2019-12-31
FR11C0053I1 (hu) 2012-01-13
NO2011027I2 (hu) 2011-12-15
LT5133B (lt) 2004-05-25
DE60104282T2 (de) 2005-10-13
EP1536234A2 (en) 2005-06-01
HU228137B1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
HUP0302201A2 (hu) Oldható CTLA4 mutáns molekulák és alkalmazásuk
Nimmerjahn et al. Antibodies, Fc receptors and cancer
JP2024019176A (ja) 系統特異的タンパク質の阻害のための組成物および方法
JP2022535130A (ja) 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
KR20220036908A (ko) 유전자 조작된 조혈 줄기 세포 및 그의 용도
MX2007012222A (es) Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
HUP0303428A2 (hu) Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
CN114729367A (zh) 用于cll1修饰的组合物和方法
JP2022524692A (ja) 抗ｔｃｒ抗体分子およびその使用
Al-Mossawi et al. The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis
JP2021511793A (ja) Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
WO2005017188A3 (en) Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
Kierkels et al. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
US20230133564A1 (en) Cd3-fusion protein and uses thereof
Shin et al. Cloning, expression and bioassay of canine CTLA4Ig
WO2021069915A1 (en) Engineered immune cell
Rogers et al. Distinct effects of CD86‐mediated costimulation on resting versus activated human CD4+ T cells
Rijkers et al. Antibody diversity and B lymphocyte-mediated immunity
Rijkers et al. Antibody diversity and B cell-mediated immunity
Matthey et al. pBM1. 1, a new pET-based vector for high efficiency expression of ETA'fusion toxins
WO2023205796A3 (en) Human ctla-4 peptide vaccines and uses thereof
HRP20210759T1 (hr) Poboljšana molekula polipeptida dvostruke specifičnosti
JP2007053999A (ja) 抗ｇｔｆ抗体及びその製造方法
Monach Mutational origin of a unique tumor-specific antigen and a role for B cells in tumor-induced immune suppression.

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: BELATACEPT; REG. NO/DATE: EU/1/11/694/001-002 20110617

Spc suppl protection certif: S1300012

Filing date: 20130412

Expiry date: 20210523

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001-002 20110623

Spc suppl protection certif: S1300012

Filing date: 20130412

Expiry date: 20210523

Extension date: 20260523